🔬GeneVentiv’s GENV-HEM is an AAV-based gene therapy for all types of hemophilia, including patients with inhibitors.
🔝ReciBioPharm will use its AAV manufacturing platform to accelerate the development of this therapy.
✅The collaboration aims to minimize manufacturing risks and meet development milestones.
Introduction:
ReciBioPharm has entered into a collaboration agreement with GeneVentiv Therapeutics to develop an adeno-associated virus (AAV)-based gene therapy for the treatment of hemophilia. This therapy, known as GENV-HEM, is a universal gene therapy that has shown efficacy and safety in preclinical studies. ReciBioPharm will utilize its AAV manufacturing platform to accelerate the development of this therapy.
- ReciBioPharm and GeneVentiv Therapeutics have partnered to advance the development of an AAV-based gene therapy for hemophilia.
- GeneVentiv’s GENV-HEM is a universal gene therapy for all types of hemophilia that has demonstrated therapeutic efficacy and safety in preclinical studies.
- ReciBioPharm will use its AAV manufacturing platform to accelerate the development of GENV-HEM.
- This collaboration will minimize manufacturing risks and ensure the timely achievement of key development milestones.
- The partnership will provide both GLP and GMP products to meet regulatory requirements and advance GENV-HEM to clinical trials.
Conclusion:
ReciBioPharm and GeneVentiv Therapeutics are collaborating to develop an AAV-based gene therapy, GENV-HEM, for the treatment of hemophilia. This partnership will leverage ReciBioPharm’s AAV manufacturing platform to accelerate the development of the therapy and minimize manufacturing risks. The successful development of GENV-HEM has the potential to revolutionize the treatment of hemophilia and improve the quality of life for patients with this bleeding disorder.
